Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03422822 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,166
- Enrollment target
NCT03422822: Completed Phase 3 study, sponsored by Pfizer.
NCT03422822 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 3,166 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (310% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03422822, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,166 participants
- Enrollment target
Study Summary
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying parent study. The efficacy and safety of two dosage strengths of Abrocitinib, 100 mg and 200 mg taken orally once daily, will be evaluated over variable lengths of study participation. The study consists of a 92 week initial treatment period followed by a variable length secondary treatment period during which subjects will receive treatment with open-label abrocitinib until availability of commercial product in their country, or until the sponsor terminates the study in that country. The B7451015 study also includes a sub-study evaluating whether abrocitinib has any potential effects on adolescent bone with regard to abnormal bone findings in knee MRI. The sub-study will be conducted in selected countries at selected sites. Eligible subjects are those who were 12 to \<18 years of age at the screening visit of the qualifying parent study and who are currently participating in the main B7451015 study. The sub-study will include serial Magnetic Resonance Imaging (MRI) annually and continue until all enrolled subjects are 18 years of age and have been imaged at least once or have discontinued/withdrawn.
Primary Outcome
The incidence of treatment emergent adverse events
Interventions
- DRUG Placebo
- DRUG Abrocitinib 200 mg
- DRUG Abrocitinib 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,166 participants |
| Start Date | 2018-03-08 |
| Est. Completion | 2025-12-22 |
| Phase | Phase 3 |
What the finished NCT03422822 record still lists
NCT03422822 is an interventional study that assigns participants to a tested intervention. Its 3,166 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (310% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03422822 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03422822 about?
NCT03422822 is a clinical study titled "Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis". B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying parent study. The efficacy and safety of two dosage strengths of Abrocitinib, 100 mg and 200 mg ta...
What is the current status of trial NCT03422822?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,166 participants. The study started on 2018-03-08. Estimated completion is 2025-12-22.
What interventions are being tested in trial NCT03422822?
The interventions under investigation include: Placebo (DRUG), Abrocitinib 200 mg (DRUG), Abrocitinib 100 mg (DRUG).
Who is sponsoring clinical trial NCT03422822?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03422822's enrollment target sits among peer trials
3,166 75th of 2000 higher than 1,926 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06224205 · 3,150 participants · NA
Digital Detection of Dementia (D Cubed) Studies: D3
- NCT02043457 · 3,200 participants
Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance
- NCT04045665 · 3,200 participants · Phase 3
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
- NCT05381766 · 3,200 participants · NA
Building Access to Food Through Systems and Solidarity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI